Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of platelet inhibition with cangrelor after discontinuation of oral P2Y12 inhibitors in acute coronary syndrome patients undergoing CABG
2008-001135-35Phase 2Completed
- Sponsor
- The Medicines Company
- Start
- Nov 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cangrelor in acute coronary syndrome (ACS), sponsored by The Medicines Company. Primary endpoints: Maintenance of platelet inhibition during cangrelor infusion before surgery and Peri-operative bleeding safety. Started Nov 2009; status: completed.
02
Drugs
cangrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2008-001135-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001135-35.